Company Mineralys Therapeutics, Inc.

Equities

MLYS

US6031701013

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:00:14 2024-05-13 pm EDT			5-day change	1st Jan Change
13.14 ^USD	-2.81%		-4.69%	+52.38%

May. 09	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Companyâs product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

Number of employees: 28

Managers	Title	Age	Since
Jon Congleton CEO	Chief Executive Officer	60	20-10-31
Adam Levy DFI	Director of Finance/CFO	46	22-02-28
Jessica Ibbitson CTO	Chief Tech/Sci/R&D Officer	-	21-02-28
David Rodman CTO	Chief Tech/Sci/R&D Officer	69	20-12-31
Minji Kim PRN	Corporate Officer/Principal	-	Jan. 03

Members of the board	Title	Age	Since
Srini Akkaraju Akkaraju BRD	Director/Board Member	56	21-01-31
Glenn Sblendorio BRD	Director/Board Member	68	23-09-12
Alexander G. Asam BRD	Director/Board Member	58	21-01-31
Daphne Karydas BRD	Director/Board Member	49	23-09-12
Olivier Litzka BRD	Director/Board Member	56	22-05-07
Jon Congleton CEO	Chief Executive Officer	60	20-10-31
Derek DiRocco BRD	Director/Board Member	43	22-05-07
BT Slingsby FOU	Founder	47	19-05-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,648,540	42,994,512 ( 86.60 %)	0	86.60 %

Name	Equities	%	Valuation
Catalys Pacific LLC 18.53 %	9,194,579	18.53 %	119 M $
Samsara Biocapital LLC 10.23 %	5,074,916	10.23 %	66 M $
TCG Crossover Management LLC 6.418 %	3,185,185	6.418 %	41 M $
RA Capital Management LP 6.404 %	3,178,476	6.404 %	41 M $
Andera Partners SCA 5.775 %	2,865,976	5.775 %	37 M $
Adams Street Partners LLC 4.639 %	2,302,329	4.639 %	30 M $
HBM Partners AG (Investment Management) 4.526 %	2,246,332	4.526 %	29 M $
Braidwell LP 4.078 %	2,023,900	4.078 %	26 M $
SR One Capital Management LP 3.616 %	1,794,600	3.616 %	23 M $
Jon Congleton 2.930 %	1,454,235	2.930 %	19 M $

Mineralys Therapeutics, Inc.

150 North Radnor Chester Road Suite F200

19087, Radnor

http://www.mineralystx.com

address Mineralys Therapeutics, Inc.(MLYS)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.52 USD

Average target price

33.5 USD

Spread / Average Target

+147.78%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MINERALYS THERAPEUTICS, INC.	+57.21%	671M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+47.07%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research